Recent Updates
Recently added Catalysts
PSNL Positive Sentiment

Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

Tuesday, October 20, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Personalis, Inc. has launched the Real-Time Variant Tracker as part of its NeXT Personal MRD test. This new feature allows for the identification of clinically significant resistance mutations and targetable variants over time. The addition aims to improve patient management by providing more detailed genomic insights during testing.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of Real-Time Variant Tracker enhances MRD testing.
  • Identifies clinically relevant resistance mutations.
  • Provides insights into therapeutically targetable variants.

Full Press Release Details

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report. These results identify clinically relevant resistance and therapeutically targetable variants over time, during NeXT Personal testing. Real-Time Variant Tracker includes variants with established clinical significance, includi

Frequently Asked Questions

What is the Real-Time Variant Tracker?

It is a feature in the NeXT Personal MRD test that tracks resistance mutations.

How does the Real-Time Variant Tracker benefit patients?

It identifies clinically relevant resistance and targetable variants over time.

What does MRD stand for?

MRD stands for molecular residual disease.

Who launched the Real-Time Variant Tracker?

Personalis, Inc. launched the Real-Time Variant Tracker.

ShareAdd on Google
Tags: PSNL Personalis NeXT Personal MRD test resistance mutations genomics
Last updated: Oct 20, 2026

Biotech snapshot

Cash runway
$213M liquidity · $9M/mo burn
~23 mo
Low dilution risk